# ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

> **NCT02609958** · PHASE2 · COMPLETED · sponsor: **ASLAN Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Varlitinib

## Key facts

- **NCT ID:** NCT02609958
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-16
- **Primary completion:** 2017-07-07
- **Final completion:** 2017-10-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609958, "ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02609958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*